Drug Combination Details
| General Information of the Combination (ID: C35334) | |||||
|---|---|---|---|---|---|
| Name | Naringin NP Info | + | Doxorubicin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Healthy individual
[ICD-11: N.A.]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| In-vitro Model | H9c2(2-1) | CVCL_0286 | Healthy | Rattus norvegicus | ||
| Experimental
Result(s) |
Naringin protects myocardial cells from doxorubicin induced apoptosis partially by inhibiting the p38MAPK pathway. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Naringin protects myocardial cells from doxorubicin?induced apoptosis partially by inhibiting the p38MAPK pathway. Mol Med Rep. 2017 Dec;16(6):9457-9463. | |||
